May 9, 2019, Some children with liver cancer may need less chemotherapy than is typically used to treat the disease, according to results from a phase 3 clinical trial.
The study, led by the NCI-supported Children’s Oncology
Group, included children and infants with the most common type of childhood
liver cancer, hepatoblastoma, whose tumors had been surgically removed when the
disease was diagnosed. Such patients subsequently receive chemotherapy to
kill any remaining cancer cells.
Liver cancer is
rare in children, and only about one-third of these patients have tumors that
can be removed surgically at the time of diagnosis.
Approximately 90% of children whose tumors are removed at
diagnosis and who receive chemotherapy survive the disease. But some survivors
develop lasting side effects of chemotherapy, including hearing loss caused by
the drug cisplatin.
Investigators were therefore interested in learning whether a
lower dose of chemotherapy could be used to reduce side effects without
In the study, children who received half of the normal amount
of chemotherapy survived as long as children who received the full amount in
previous trials, researchers reported in The Lancet on April 8.
“We found that four cycles of chemotherapy—the standard
amount—were not needed and that two cycles seemed to be enough,” said Howard
Katzenstein, M.D., of Nemours Children’s Specialty Care and Wolfson Children’s
Hospital in Jacksonville, FL, one of the investigators.
The trial is part of a broader effort by the Children’s
Oncology Group and other cancer researchers to evaluate treatment regimens for
children with cancerExit Disclaimer that can reduce the risk of side effects without
increasing the chances the disease will return.
Focusing on Patients’ Quality of Life
For children with hepatoblastoma who receive “up-front”
surgery, it is common to administer chemotherapy in the hospital. In addition
to extending the length of a hospital stay, chemotherapy may cause side effects
during treatment, such as nausea, vomiting, risk of infection, and kidney
damage, Dr. Katzenstein noted.
“In a group of patients with a 90% cure rate, we need to
ensure that these children have the best possible quality of life,” said Dr.
Katzenstein. The goal of the trial, which also included other patients whose
tumors could not be surgically removed at diagnosis, was to “optimize” the
amount of adjuvant chemotherapy needed to cure the patients.
In the study, 49 patients with hepatoblastoma who had surgery
at diagnosis received two cycles of a combination of three chemotherapy drugs
(cisplatin, fluorouracil, and vincristine) rather than the standard four
After a median follow-up of 42 months, more than 90% of
patients in the trial had no symptoms of liver cancer or a recurrence of the disease
(an outcome known as event-free survival), the researchers found. This result
compares well with the results of previous trials involving surgery plus four
cycles of chemotherapy, they noted.
Only one patient in the trial experienced hearing loss. After
a median follow-up of 4 years, 95% of the patients were alive; the 5-year
overall survival rate was 91%.
“The results of this trial will inform decisions about how
the disease is treated in the future,” said Nita Seibel, M.D., head of
Pediatric Solid Tumor Therapeutics in NCI’s Cancer Therapy Evaluation Program,
who was not involved in the study.
She cautioned, however, that the study was small and that the
findings apply only to the care of patients with tumors that surgeons can
safely remove at diagnosis. Patients are not candidates for the reduced amount
of chemotherapy if their tumors are advanced or have spread to other parts of
“The trial builds on the work of a previous study that
reduced the number of cycles of chemotherapy for some patients with
hepatoblastoma from six to four,” Dr. Seibel continued. “The ultimate goal of
this research is to reduce the amount of chemotherapy a patient needs without
But progress in reaching this goal has been “gradual,” she added,
in part because pediatric liver cancer is so rare. Only about 100 to 125 cases
of hepatoblastoma are diagnosed in North America each year.
“Hopefully we will get to a point when some of these children
may be treated with surgery alone and not receive [any] chemotherapy, but we’re
not there yet,” she said.
Guidelines for Selecting Patients for Surgery
As the new results demonstrate, liver cancer “is a very
treatable” disease for children with hepatoblastoma that can be surgically
removed at diagnosis, said Greg Tiao, M.D., a pediatric surgeon at Cincinnati
Children’s Hospital and an investigator on the trial.
To help doctors identify children with hepatoblastoma who can
safely undergo surgery at diagnosis, Rebecka Meyers, M.D., of the University of
Utah Hospital and an investigator on the trial, led a team that developed
guidelines for identifying tumors that can be removed safely based on imaging
For example, patients with tumors that affect part of the
liver, rather than the entire liver, may be candidates for surgery.
These guidelines were incorporated into the clinical trial.
Until now, surgeons have relied primarily on their own knowledge and experience
to decide which patients were candidates to have their tumors removed.
“But even surgeons at large medical centers who see children
with cancer might only see one or two patients with hepatoblastoma each year,”
said Dr. Tiao.
Follow-up and larger studies will be needed to determine how
the use of the guidelines may influence the selection of patients and patient
outcomes, the researchers noted.
An International Trial for Children with Liver Cancer
The approach of using fewer cycles of chemotherapy following
surgery for children newly diagnosed with hepatoblastoma is being evaluated
further in a large international clinical trial that is under way in North
America, Europe, Japan, and Australia.
This study will assess various treatment
approaches in approximately 1,200 children.
For example, some patients whose tumors cannot be removed surgically at diagnosis will initially receive chemotherapy to reduce the size of their tumors, potentially making it possible for the tumors to be removed by surgery.
- Justice Katju writes to Yogi Adityanath on misbehaviour with Kashmiri dry fruit vendors in Lucknow
- Minorities in Pakistan: Jinnah’s words proved cruel mockery and a burlesque
- Increasing Climate Impacts puts coastal communities & their livelihoods at risk, yet Budget allocation for NCM is lower
- Shadow pandemic: Gender-based violence is one of the biggest human rights violations
- #Breaking: Latest News |Today’s big news headlines | 02 February 2023 news.
The trial is expected to provide the evidence that will help
to establish standard treatments for all patients with hepatoblastoma in the
“This is the first trial in hepatoblastoma that’s truly been organized internationally,” said Dr. Katzenstein. “The results will provide the evidence base from a large international study to know when we can safely give patients less chemotherapy and thereby avoid the problems associated with it.”
“Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests was originally published by the National Cancer Institute.”